With 10 cases in 2025, Guinea worm could be the second disease ever eradicated. Here is what makes disease eradication ...

Roche's AXELIOS 1 enters next generation DNA sequencing. Can it or rivals unseat Illumina's long-standing market dominance?

New therapies in the clinic for bipolar disorder hope to meet unmet needs of efficacy and minimal side effects.

Europe’s pandemic preparedness capital is creating a rare opening for biotech innovators. Since COVID-19, the next pandemic is no longer abstract, and preparedness is no longer optional. Europe is ...

Munich has long been recognized as one of Germany’s scientific powerhouses, but in recent years it has also emerged as one of Europe’s most dynamic biotech and life sciences ecosystems. Bringing ...

Research in the field of inflammatory diseases has become one of the hottest areas of drug development, spurred on by an interest in novel therapies that have the potential to be more precise and more ...

Antibody–drug conjugates (ADCs) combine the targeting ability of monoclonal antibodies with the cell-killing effects of potent cytotoxic drugs. Over the past decade, the approach has moved from ...

Hemophilia is a rare, genetic disorder in which the blood does not clot enough to make bleeding slow down or stop. This is because patients with hemophilia do not have the normal amount of clotting ...

Unlike traditional drugs that bind directly to a protein’s active site, allosteric modulators act at separate regulatory sites, allowing them to fine-tune biological activity and act more like a ...

For a long time, neurological drug development has largely focused on the cells that ultimately die or malfunction. Alzheimer’s researchers chased amyloid and tau. Parkinson’s drug development ...

The biopharma industry has seen its fair share of clinical and financial failures. When biotechs face setbacks, their stock values plummet and they lack the funds to develop new medicines, restructure ...